KOREA WHO
-
-
-
CEO of Peptron
Choi Ho-il
First-Generation Bio Venture Pioneer, Leading Global Market with Innovative Peptide Drugs
-
Last Updated on May 14, 2025
-
CEO of Peptron
Life Summary
Choi Ho-il is the CEO of Peptron.
He is regarded as a pioneer in the field of sustained-release peptide drug development.
He was born in September 1966.
He graduated from the Department of Biochemistry at Yonsei University. He earned both his master’s and doctoral degrees in biochemistry from the graduate school of Yonsei University.
He built his research and development experience at the Korea Research Institute of Bioscience and Biotechnology and LG Chemical Biotech (now LG Life Sciences), before establishing Peptron independently in November 1997.
He is considered part of the first generation of biotech venture entrepreneurs in Korea.
After personally suffering from a skin condition, he devoted himself to developing long-acting pharmaceutical products to eliminate the inconvenience of frequent medication.
#ChoiHoil #Peptron #KoreanBiotech #Biopharmaceuticals #PeptideDrugs #DrugDelivery #YonseiUniversity #BiotechPioneer #PharmaInnovation #SkinDisorderTreatment
He is regarded as a pioneer in the field of sustained-release peptide drug development.
He was born in September 1966.
He graduated from the Department of Biochemistry at Yonsei University. He earned both his master’s and doctoral degrees in biochemistry from the graduate school of Yonsei University.
He built his research and development experience at the Korea Research Institute of Bioscience and Biotechnology and LG Chemical Biotech (now LG Life Sciences), before establishing Peptron independently in November 1997.
He is considered part of the first generation of biotech venture entrepreneurs in Korea.
After personally suffering from a skin condition, he devoted himself to developing long-acting pharmaceutical products to eliminate the inconvenience of frequent medication.
#ChoiHoil #Peptron #KoreanBiotech #Biopharmaceuticals #PeptideDrugs #DrugDelivery #YonseiUniversity #BiotechPioneer #PharmaInnovation #SkinDisorderTreatment